Pfizer News and Research RSS Feed - Pfizer News and Research

Nicotine metabolism linked with chronic alcohol abuse may contribute to poor smoking cessation rates

Nicotine metabolism linked with chronic alcohol abuse may contribute to poor smoking cessation rates

For smokers who are addicted to alcohol, chronic alcohol abuse may increase the rate of nicotine metabolism and contribute to poor smoking cessation rates. When smokers stop drinking the nicotine metabolism rates decline significantly, according to a study conducted by an international research team led by Roswell Park Cancer Institute. The research was a collaboration of scientists from Roswell Park, the University of California, San Francisco, and the Medical University of Silesia and Center of Addiction Treatment in Poland. [More]
Bupropion, varenicline drugs do not increase risk of serious neuropsychiatric adverse events

Bupropion, varenicline drugs do not increase risk of serious neuropsychiatric adverse events

Compared to the nicotine patch and a placebo, the smoking cessation aids varenicline (marketed as Chantix in the U.S.) and bupropion (Zyban) do not show a significant increase in neuropsychiatric adverse events, reports an international team of researchers in a study published online April 22 in the journal The Lancet. [More]
New drug combination before surgery may improve outcomes in breast cancer patients

New drug combination before surgery may improve outcomes in breast cancer patients

Results from the I-SPY 2 trial show that giving patients with HER2-positive invasive breast cancer a combination of the drugs trastuzumab emtansine (T-DM1) and pertuzumab before surgery was more beneficial than the combination of paclitaxel plus trastuzumab. [More]
Studies confirm benefit of plasma genotyping to predict treatment outcomes for NSCLC patients

Studies confirm benefit of plasma genotyping to predict treatment outcomes for NSCLC patients

The benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer (NSCLC) is confirmed in three studies presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland. Researchers however warned that plasma tests are unlikely to fully replace tissue biopsies. [More]
Stanford study reveals that smokers remain unemployed longer compared to nonsmokers

Stanford study reveals that smokers remain unemployed longer compared to nonsmokers

A one-year longitudinal study by researchers at the Stanford University School of Medicine strongly suggests that smokers remain unemployed longer than nonsmokers. And when smokers do find jobs, they earn substantially less than nonsmokers. [More]
Evolocumab could be more effective than ezetimibe in lowering cholesterol in statin-intolerant patients

Evolocumab could be more effective than ezetimibe in lowering cholesterol in statin-intolerant patients

In the first major trial of its kind, Cleveland Clinic researchers used a blinded rechallenge with atorvastatin or placebo to objectively confirm the presence of muscle-related symptoms in patients with a history of intolerance to multiple statins and found that evolocumab (a PCSK9 inhibitor) was a more effective option to lower cholesterol than ezetimibe in these patients. [More]
Combining aromatase inhibitors with growth hormone may help short adolescent boys grow taller

Combining aromatase inhibitors with growth hormone may help short adolescent boys grow taller

Aromatase inhibitors, when used for up to three years in combination with growth hormone, may effectively and safely help very short adolescent boys grow taller, new research suggests. The study results will be presented Sunday, April 3, at ENDO 2016, the annual meeting of the Endocrine Society in Boston. [More]
Study demonstrates rarity of familial hypercholesterolemia mutations in individuals with high cholesterol

Study demonstrates rarity of familial hypercholesterolemia mutations in individuals with high cholesterol

Only a small fraction of people with very high cholesterol can attribute their condition to a genetic mutation related to familial hypercholesterolemia, but individuals with these mutations face a high risk of developing early-onset coronary artery disease, according to research presented at the American College of Cardiology's 65th Annual Scientific Session. [More]
High out-of-pocket costs linked to lower use of specialty drugs

High out-of-pocket costs linked to lower use of specialty drugs

"Specialty drugs" have become important treatment options for many serious and chronic diseases, and in some conditions like cancer they represent the only chance for long-term survival. [More]
Failure to complete antibiotics could lead to additional treatment for existing skin infection

Failure to complete antibiotics could lead to additional treatment for existing skin infection

In the first study of its kind, researchers found patients with S. aureus skin and soft tissue infections took, on average, just 57% of their prescribed antibiotic doses after leaving the hospital, resulting in nearly half of them getting a new infection or needing additional treatment for the existing skin infection. [More]
Breckenridge Pharmaceutical announces final FDA approval for Gabapentin Oral Solution

Breckenridge Pharmaceutical announces final FDA approval for Gabapentin Oral Solution

Breckenridge Pharmaceutical, Inc. announces the final approval by the U.S. Food and Drug Administration of the Abbreviated New Drug Application for Gabapentin Oral Solution 250 mg per 5 mL, which is AA rated to Neurontin, a drug marketed by Pfizer. [More]
Halozyme Therapeutics doses first patient in Halo-301 | Pancreatic study

Halozyme Therapeutics doses first patient in Halo-301 | Pancreatic study

Halozyme Therapeutics, Inc., a biotechnology company developing novel oncology and drug-delivery therapies, today announced the first patient has been dosed in its Halo-301 | Pancreatic study, a Phase 3 clinical trial in previously untreated metastatic pancreatic cancer patients. [More]

Pittcon 2015: Bruker introduces InsightMR software for on-line NMR analysis of chemical processes

Bruker is launching InsightMR software for on-line NMR analysis of chemical processes at Pittcon 2015. For the first time, a software platform enables the adjustment of experimental parameters based on real time data during the analysis of chemical processes by NMR spectroscopy. [More]
Bruker showcases innovative NMR solutions for pharmaceutical industry at ENC 2015

Bruker showcases innovative NMR solutions for pharmaceutical industry at ENC 2015

At the 56th Experimental Nuclear Magnetic Resonance Conference, Bruker this week is show-casing several innovative drug discovery, drug development and process control solutions for small molecule NMR characterization in the pharmaceutical industry. [More]
FDA approves Xalkori (crizotinib) to treat patients with ROS-1 positive NSCLC

FDA approves Xalkori (crizotinib) to treat patients with ROS-1 positive NSCLC

The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Xalkori is the first and only FDA approved treatment for patients with ROS-1 positive NSCLC. [More]
Popular kidney cancer drugs do not reduce incidence of recurrence

Popular kidney cancer drugs do not reduce incidence of recurrence

Two widely used targeted therapy drugs approved by the FDA for the treatment of metastatic kidney cancer—sorafenib and sunitinib—are no more effective than a placebo in preventing return of the disease to increase life spans of patients suffering from advanced kidney cancer after surgery, according to a new multi-institutional study in the Lancet led by a researcher at the Abramson Cancer Center (ACC) of the University of Pennsylvania. [More]
Complex biomarker tests for molecularly targeted therapies lack evidentiary standards

Complex biomarker tests for molecularly targeted therapies lack evidentiary standards

Potentially useful biomarker tests for molecularly targeted therapies are not being adopted appropriately into clinical practice because of a lack of common evidentiary standards necessary for regulatory, reimbursement, and treatment decisions. [More]
New co-marketing deal to make AMRA Profiler protocol available on future GE Healthcare MRI scanners

New co-marketing deal to make AMRA Profiler protocol available on future GE Healthcare MRI scanners

AMRA has announced at the European Congress of Radiology in Vienna, Austria, that it has entered into a new co-marketing agreement with GE Healthcare, a leading provider of MRI systems. [More]
First-ever research programme launched to tackle superbugs

First-ever research programme launched to tackle superbugs

To meet the challenge of the rise in antibiotic resistant bacteria, national charity ‘Antibiotic Research UK is commissioning the first ever research programme to screen antibiotic resistance breakers against antibiotic resistance in Gram-negative bacteria. [More]
Drug combination improves glucose control in Type 2 diabetes patients

Drug combination improves glucose control in Type 2 diabetes patients

A multinational clinical trial led by UT Southwestern Medical Center and others found that injection of a new long-acting insulin combined with another drug improves glucose control in patients with Type 2 diabetes and, additionally, is associated with weight loss. [More]
Advertisement
Advertisement